Paxillin
From Proteopedia
(Difference between revisions)
Line 25: | Line 25: | ||
**[[4xgz]], [[4xh2]] – hPXN + antibody<br /> | **[[4xgz]], [[4xh2]] – hPXN + antibody<br /> | ||
**[[1ow8]], [[1ow7]] – hPXN + focal adhesion kinase focal adhesion targeting domain <br /> | **[[1ow8]], [[1ow7]] – hPXN + focal adhesion kinase focal adhesion targeting domain <br /> | ||
- | **[[5w93]] – | + | **[[5w93]] – mPXN + P130CAS - mouse<br /> |
*Paxillin LD4 (residues 20-41) | *Paxillin LD4 (residues 20-41) | ||
Line 41: | Line 41: | ||
**[[5uwh]] – hPXN + RAN + CRM1 + RANBP1<br /> | **[[5uwh]] – hPXN + RAN + CRM1 + RANBP1<br /> | ||
**[[3u3f]] – hPXN + tyrosine kinase PYK2 focal adhesion domain<br /> | **[[3u3f]] – hPXN + tyrosine kinase PYK2 focal adhesion domain<br /> | ||
+ | **[[6jmu]] – mPXN + GIT1<br /> | ||
*Paxillin proline-rich region (residues 45-54) | *Paxillin proline-rich region (residues 45-54) |
Current revision
|
3D structures of paxillin
Updated on 17-September-2020
References
- ↑ Tumbarello DA, Brown MC, Turner CE. The paxillin LD motifs. FEBS Lett. 2002 Feb 20;513(1):114-8. PMID:11911889
- ↑ Jagadeeswaran R, Surawska H, Krishnaswamy S, Janamanchi V, Mackinnon AC, Seiwert TY, Loganathan S, Kanteti R, Reichman T, Nallasura V, Schwartz S, Faoro L, Wang YC, Girard L, Tretiakova MS, Ahmed S, Zumba O, Soulii L, Bindokas VP, Szeto LL, Gordon GJ, Bueno R, Sugarbaker D, Lingen MW, Sattler M, Krausz T, Vigneswaran W, Natarajan V, Minna J, Vokes EE, Ferguson MK, Husain AN, Salgia R. Paxillin is a target for somatic mutations in lung cancer: implications for cell growth and invasion. Cancer Res. 2008 Jan 1;68(1):132-42. doi: 10.1158/0008-5472.CAN-07-1998. PMID:18172305 doi:http://dx.doi.org/10.1158/0008-5472.CAN-07-1998